Published by Frank Prenesti on 25th October 2022
(Sharecast News) - AstraZeneca said its Fasenra treatment for a rare inflammatory disease of the oesophagus failed to meet one of the two dual-primary endpoints in a phase 3 trial.
URL: http://www.digitallook.com/dl/news/story/33057681/...